SUBSCRIBE
SUBSCRIBE

Priovant Therapeutics

NEWS
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Immunology and inflammation
Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study
According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.
February 6, 2026
 · 
2 min read
 · 
Tristan Manalac
Pierre Suu/Getty Images
Business
Pfizer, Roivant Unveil Priovant with High Potential TYK2/JAK1 Inhibitor
Pfizer and Roivant unveiled Priovant Therapeutics to develop and market new therapies for a wide range of autoimmune diseases with high mortality and morbidity rates.
June 28, 2022
 · 
2 min read
 · 
Vanessa Doctor, RN
JOBS
IN THE PRESS
Press Releases
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
February 8, 2026
 · 
6 min read
Press Releases
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
September 18, 2025
 · 
10 min read
Press Releases
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
June 10, 2025
 · 
4 min read
Press Releases
Priovant Therapeutics Announces Receipt of Fast Track Designation from FDA for Brepocitinib in Non-Anterior Non-Infectious Uveitis (NIU) & Start of Enrollment of Brepocitinib Phase 3 NIU Program
September 23, 2024
 · 
6 min read
Press Releases
Priovant Therapeutics Announces Completion of Enrollment in Global Phase 3 Study Evaluating Brepocitinib in Dermatomyositis (VALOR)
July 29, 2024
 · 
7 min read
Drug Development
Priovant Therapeutics Announces Positive Phase 2 NEPTUNE Study Results for Brepocitinib in Non-Infectious Uveitis (NIU), Showing Strongest Efficacy Data in NIU Observed to Date
April 2, 2024
 · 
7 min read
Pharm Country
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
April 2, 2024
 · 
12 min read
Business
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
November 27, 2023
 · 
5 min read
Bio NC
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
June 28, 2022
 · 
11 min read